On November 25, 2025, Sarepta Therapeutics filed two petitions for inter partes review (“IPR”) challenging Genzyme’s patents relating to ...

Wedbush has initiated Sarepta Therapeutics (SRPT) at outperform saying that a selloff that began earlier this year following ...

The financing exercise at Sarepta Therapeutics continues as uncertainty remains for the company’s flagship gene therapy Elevidys. The Massachusetts biopharma has reached an agreement with some ...

The company said in a statement that the FDA notified it on Monday and plans to resume shipping Elevidys to sites of care for treatment of ambulatory patients with Duchenne “imminently. “ The FDA ...

Acute liver injury has been associated with the death of two non-ambulatory DMD patients treated with Elevidys.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced that the U.S. Food and Drug Administration (FDA ...

Sarepta Therapeutics, Inc. SRPT reported second-quarter 2025 adjusted EPS of $2.02, which beat the Zacks Consensus Estimate of $1.11. This beat was mainly due to higher-than-expected collaboration ...

Sarepta (SRPT) will begin shipping its top-selling muscular dystrophy therapy, Elevidys, after the US Food and Drug Administration (FDA) reversed its request for a voluntary pause late Monday. The ...

- Sarepta and FDA will continue dialogue on next steps in the safety labeling process and risk-mitigation approach for non-ambulatory patients Sarepta will resume shipping ELEVIDYS to sites of care ...

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an update to the prescribing information for ELEVIDYS (delandistrogene ...

Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts attributed in part to a milestone payment for its controversial gene therapy ...

- Sarepta and FDA will continue dialogue on next steps in the safety labeling process and risk-mitigation approach for non-ambulatory patients CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Sarepta Therapeutics, ...